Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL XR 10 vs CHEMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall XR 10 contains a mixture of amphetamine salts, which are central nervous system stimulants. The dextroamphetamine and levoamphetamine components increase synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals. This action leads to enhanced neurotransmission in the prefrontal cortex and other brain regions involved in attention and executive function.
Chelates heavy metals, particularly lead, mercury, and arsenic, by forming soluble complexes that are excreted renally. Acts as an antidote by binding to toxic metals and reducing their tissue concentrations.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy (off-label)
Treatment of acute and chronic lead poisoning,Treatment of mercury poisoning,Treatment of arsenic poisoning,Diagnostic chelation challenge test
10 mg orally once daily in the morning; maximum dose 40 mg/day.
10-20 mg/kg orally every 8 hours for 5 days; maximum single dose 1250 mg.
Dexamphetamine: 10-13 hours in adults (children: 6-8 hours); levoamphetamine: 13-16 hours; clinically, steady-state achieved in approximately 3 days, with twice-daily dosing maintaining therapeutic levels
Terminal elimination half-life: 1.6–3.5 hours (mean 2.1 h) in adults with normal renal function; prolonged in renal impairment (up to 20 h).
Amphetamine is primarily metabolized by hepatic CYP2D6 to 4-hydroxyamphetamine, which is further conjugated. Minor pathways include N-dealkylation and deamination. The drug has a half-life of approximately 10-13 hours.
Metabolized in liver to disulfide dimers; undergoes enterohepatic circulation; primarily excreted renally as metabolites and unchanged drug.
Renal (approximately 30-40% as unchanged amphetamine, remainder as metabolites, including deaminated and oxidized products; urinary p H-dependent elimination: acidic p H increases renal clearance, alkaline p H decreases renal clearance; negligible biliary/fecal elimination)
Renal: 80–90% as unchanged drug and metabolites (primarily as chelated complexes); biliary/fecal: <10%.
15-40% bound to plasma proteins, primarily albumin; lower binding in patients with hepatic impairment
Approximately 80% bound to plasma proteins, primarily albumin.
3.0-4.5 L/kg for total amphetamine; high tissue distribution (brain, lungs, kidneys); enters CNS via passive diffusion and active transport
0.5–0.8 L/kg, indicating distribution mainly in extracellular fluid; limited intracellular penetration.
Oral: quantitative absorption with 90-100% bioavailability of the total amphetamine content; food does not affect overall absorption but may delay peak concentrations with high-fat meals
20–40% after oral administration due to first-pass metabolism and limited absorption.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: not recommended.
GFR 50-80 m L/min: same dose every 12 hours. GFR 10-49 m L/min: same dose every 24 hours. GFR <10 m L/min: same dose every 48 hours.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
No specific recommendations; caution in severe hepatic impairment (Child-Pugh C) due to potential toxicity.
Children 6-17 years: starting dose 5 mg once daily; increase by 5 mg weekly based on response; maximum 30 mg/day.
Children >1 year: 10-20 mg/kg/dose orally every 8 hours for 5 days; maximum 1250 mg/dose.
Starting dose 5 mg once daily; increase cautiously with monitoring for hypertension, agitation, and cognitive effects.
Consider starting at lower end of dosing range (10 mg/kg) due to potential renal impairment; adjust per renal function.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including Adderall XR, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
None
Serious cardiovascular events, including sudden death in patients with pre-existing structural cardiac abnormalities; blood pressure and heart rate increases; psychiatric adverse reactions (e.g., exacerbation of psychosis, mania, aggression); seizures; serotonin syndrome if combined with serotonergic drugs; long-term growth suppression in children; peripheral vasculopathy including Raynaud's phenomenon; potential for abuse and dependence.
May cause nephrotoxicity; monitor renal function,May cause hypersensitivity reactions, including fever, rash, and anaphylaxis,Monitor for neutropenia; obtain CBC before and during therapy,Use caution in patients with hepatic impairment or glucose-6-phosphate dehydrogenase (G6PD) deficiency,May chelate essential minerals (e.g., zinc, copper); monitor levels with prolonged use,Not recommended for routine use in asymptomatic lead poisoning with low blood lead levels
Hypersensitivity to amphetamine or any component of the formulation; patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma; agitated states; history of drug abuse; during or within 14 days following MAOI therapy.
Hypersensitivity to dimercaprol or any component of the formulation,Hepatic failure (except severe heavy metal poisoning),Concurrent use with iron (increases nephrotoxicity); avoid iron therapy within 24 hours,Pregnancy (if not life-saving indication due to risk of teratogenicity),Peanut allergy (formulation contains peanut oil)
Take ADDERALL XR with or without food. However, high-fat meals may delay absorption and reduce peak concentrations. Avoid consumption of acidic foods or beverages (e.g., citrus fruits, fruit juices, cola) within 1 hour before or after dosing, as acidity can decrease absorption. Vitamin C (ascorbic acid) and other acidifying agents can reduce efficacy; conversely, alkalizing agents (e.g., antacids, sodium bicarbonate) may potentiate effects.
No specific food interactions reported. However, due to gastrointestinal side effects (nausea, vomiting), it is advisable to maintain small, frequent meals. Avoid alcohol.
Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations (ventricular septal defects) and neural tube defects at high doses. Second trimester: Potential for reduced fetal growth and premature delivery. Third trimester: Risk of neonatal withdrawal syndrome (irritability, dysphoria, tremor, hypertonia) and preterm birth.
FDA Pregnancy Category C. First trimester: No adequate studies, but animal studies show fetal resorption at maternally toxic doses, risk cannot be excluded. Second and third trimesters: No specific teratogenicity, but may cause anemia in fetus due to maternal chelation of essential metals. Avoid use unless clearly needed.
Contraindicated during breastfeeding. Amphetamine is excreted into human milk; M/P ratio approximately 3.5. Infant exposure estimated at 4-8% of maternal weight-adjusted dose. Reported adverse effects in infants include irritability, poor feeding, and sleep disturbances.
No human data on excretion in breast milk. M/P ratio unknown. Caution due to potential for infant exposure and chelation of trace elements; consider benefit-risk. Avoid breastfeeding during therapy and for 2 weeks after last dose.
Increased clearance during 2nd and 3rd trimesters (hepatic induction) may require dose escalation. Postpartum, clearance returns to nonpregnant levels, requiring dose reduction to avoid toxicity. Individualize dosing based on clinical response and tolerability.
No specific dose adjustments recommended for pregnancy. Increased plasma volume in pregnancy may alter pharmacokinetics, but studies not performed. Use lowest effective dose; monitor therapeutic response and toxicity closely.
ADDERALL XR (mixed amphetamine salts extended-release) 10 mg is a CNS stimulant indicated for ADHD. Initiate at 10 mg once daily in the morning; titrate in 5-10 mg increments weekly. Swallow capsules whole, or sprinkle contents on applesauce for patients unable to swallow. Avoid afternoon doses to prevent insomnia. Monitor for hypertension, tachycardia, and growth suppression in children. Abuse potential is high; use with caution in patients with history of substance abuse. Contraindicated in glaucoma, hyperthyroidism, agitated states, MAOI use within 14 days, and structural cardiac abnormalities.
Chelation therapy with dimercaprol (CHEMET) should be initiated within 4 hours of arsenic or mercury exposure for maximal efficacy. Administer only via deep intramuscular injection, never intravenously. Monitor renal function and urine output closely, as dimercaprol can cause nephrotoxicity. Alkalinize urine to p H 7.5-8.5 to decrease renal precipitation of metal-drug complexes. Use with caution in patients with glucose-6-phosphate dehydrogenase deficiency due to risk of hemolysis. Contraindicated in patients with peanut allergy (vehicle is peanut oil).
Take exactly as prescribed once daily in the morning with or without food.,Do not chew or crush the capsule; you may open it and sprinkle the beads on a spoonful of applesauce, then swallow immediately without chewing.,Avoid taking in the afternoon or evening as it may cause difficulty sleeping.,Do not stop abruptly without consulting your doctor; sudden discontinuation may cause withdrawal symptoms.,Report any chest pain, palpitations, shortness of breath, or fainting to your doctor.,This medication has a high potential for abuse; keep in a safe place and do not share with others.,Avoid alcohol and illicit drugs while taking this medication.,Notify your doctor if you have a history of drug dependence, anxiety, bipolar disorder, or seizures.,For patients with ADHD, it may improve focus, attention, and impulse control.,Store at room temperature away from moisture and heat.
This medication is given as a shot into a muscle, usually in the buttock. It may cause pain at the injection site.,You may experience a metallic taste, nausea, vomiting, headache, or burning sensation in the mouth or throat.,Drink plenty of fluids unless otherwise instructed to help flush metals from your body.,Avoid alcohol during treatment and for at least 48 hours after the last dose.,Report any signs of allergic reaction (rash, itching, difficulty breathing) or dark urine immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL XR 10 vs CHEMET, answered by our medical review team.
ADDERALL XR 10 is a CNS Stimulant that works by Adderall XR 10 contains a mixture of amphetamine salts, which are central nervous system stimulants. The dextroamphetamine and levoamphetamine components increase synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals. This action leads to enhanced neurotransmission in the prefrontal cortex and other brain regions involved in attention and executive function.. CHEMET is a Chelating agent that works by Chelates heavy metals, particularly lead, mercury, and arsenic, by forming soluble complexes that are excreted renally. Acts as an antidote by binding to toxic metals and reducing their tissue concentrations.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL XR 10 and CHEMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL XR 10 is: 10 mg orally once daily in the morning; maximum dose 40 mg/day.. The standard adult dose of CHEMET is: 10-20 mg/kg orally every 8 hours for 5 days; maximum single dose 1250 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL XR 10 and CHEMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL XR 10 is classified as Category C. Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations (ventricular septal defects) and neural tube defects a. CHEMET is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate studies, but animal studies show fetal resorption at maternally toxic doses, risk cannot be excluded. Second and third trimes. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.